Announcements
- Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
- Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
- Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
- Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Abeona Therapeutics Provides Regulatory Update on Pz-cel
- Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
- Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Announces $50 Million Credit Facility
More ▼
Key statistics
On Friday, Abeona Therapeutics Inc (0H7R:LSE) closed at 5.06, 74.46% above the 52 week low of 2.90 set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 5.06 |
Low | 5.06 |
Bid | -- |
Offer | -- |
Previous close | 5.06 |
Average volume | 1.19k |
---|---|
Shares outstanding | 40.96m |
Free float | 39.64m |
P/E (TTM) | -- |
Market cap | 222.02m USD |
EPS (TTM) | -3.20 USD |
Data delayed at least 20 minutes, as of Jul 19 2024 15:59 BST.
More ▼